Details

The second of EASL's live webinars on COVID-19 addresses the topic of vaccination in patients with liver disease. This was chaired by Professor Ulrich Spengler and Professor Verena Keitel, who were joined by Dr Thomas Marjot, Professor Julian Schulze-zur-Wiesch, Professor Dr Miriam Sturkenboom and Professor Rifaat Safadi. Dr Marjot presented on the prioritizing liver disease patients for COVID-19 vaccination followed by an Overview of COVID-19 vaccines available in Europe presented by Professor Schulze-zur-Wiesch. Professor Sturkenboom presented the Benefit/risk of COVID-19 vaccinations: current knowledge and specific populations before Professor Safadi closed with the First practical experiences with COVID-19 vaccinations in Israeli patients with liver disease. A fascinating Q&A session after the main presentations covered a range of topics including how to monitor vaccine efficacy in liver disease patients, what needs to be done in countries with limited supply, whether COVID-19 vaccines can be combined with others and recommendations for specific patient profiles.

Target Audience

  • Hepatologists, gastroenterologists
  • General practitioners
  • Health care professionals
  • Clinical scientists
  • Basic scientists

Learning Objectives

  • Learn about the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations
  • Learn about the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases
  • Learn about the scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases
  • Learn about the first outcome data of population-based vaccination in patients with and without liver diseases

 

Title

Welcome & Introduction

Ulrich Spengler, University of Bonn, Germany

Verena Keitel, University Hospital of Düsseldorf, Germany

Defining liver patients in urgent need of a COVID-19 vaccine for priorisation

Thomas Marjot, University of Oxford, United Kingdom

Overview of the COVID-19 vaccines available in Europe

Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany

Benefit/Risk of COVID-19 vaccinations: Current knowledge and how it translates to specific populations

Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Netherlands

First practical experiences with COVID-19 vaccination in Israeli patients with liver disease

Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel

Discussion and Q&A

All

 

Watch the full on-demand webinar

 

Defining liver patients in urgent need of a COVID-19 vaccine for priorisation

 

Overview of the COVID-19 vaccines available in Europe

 

Benefit/Risk of COVID-19 vaccinations: Current knowledge and how it translates to specific populations

 

First practical experiences with COVID-19 vaccination in Israeli patients with liver disease

 

Ulrich Spengler

Ulrich Spengler is Professor Emeritus at the Rheinische Friedrich-Wilhelms University of Bonn in Germany. He is also a member of the European Association for the Study of the Liver (EASL) Educational Committee. A certified specialist in internal medicine, gastroenterology and infectious diseases, Professor Spengler’s expertise and scientific interest is in the immunity aspects of liver diseases and infections of the liver.

Verena Keitel

Verena Keitel is Professor of Hepatobiliary Transport Physiology and a senior physician at the Department of Gastroenterology, Hepatology and Infectious Diseases at the University Hospital Düsseldorf in Germany. Her clinical and research interests focus on cholestatic and hereditary liver diseases and the improvement of patient care. She is also a part of the German Collaborative Research Center Steering Committee.

Thomas Marjot

Thomas Marjot is a Hepatology Specialist Registrar and Wellcome Trust Clinical Research Training Fellow at the University of Oxford, UK. He has a particular research interest in the lipid flux pathways leading to non-alcoholic fatty liver disease (NAFLD). Since the onset of the pandemic, Dr Marjot has led the European Association for the Study of the Liver (EASL)-supported COVID-Hep registry designed to characterise the COVID-19 disease course in patients with chronic liver disease or after liver transplantation. The COVID-Hep registry has just been relaunched with EASL in partnership with North American collaborators SECURE-Liver to try and answer new important questions including the rates and disease course of post-vaccination SARS-CoV-2 infection.

Julian Schulze-zur-Wiesch

Julian Schulze-zur-Wiesch is a Professor in the Department of Medicine, Gastroenterology, Infectious Diseases and Tropical Medicine at the University Medical Center Hamburg-Eppendorf (UKE), Germany, where he works alongside Professor Ansgar Lohse. He is also Director of the Viral Hepatitis Outpatient Clinic at UKE, a position he assumed his 2010. Professor Schulze-zur-Wiesch did his postdoctoral training at Harvard University between 2003 and 2006.

Miriam Sturkenboom

Miriam Sturkenboom is a Professor in Observational Data Analysis, a pharmacoepidemiologist, and currently Head of the Department of Datascience and Biostatistics at the Julius Center, part of University Medical Center Utrecht, The Netherlands. A past President of the International Society for Pharmacoepidemiology, she is Coordinator of the European Commission-funded ConcePTION project aiming to establish a testing system for monitoring the benefits and risks of medicines in pregnancy and is Co-founder and President of the Vaccine Monitoring Collaboration for Europe (VAC4EU).

Rifaat Safadi

Rifaat Safadi is Director of the Liver Unit and Full Professor in Medicine, Gastroenterology and Hepatology in the Institute of Gastroenterology and Liver Diseases, Faculty of Medicine at Hadassah Hebrew University Medical Center in Ein-Kerem, Jerusalem, Israel. He is also Director of Liver Unit and Clinical Research Center at the Holy Family Hospital in Nazareth, Israel, as well as a Visiting Scholar at the Division of Liver Diseases at Mount Sinai School of Medicine, New York, USA. Professor Safadi is a leading member of several international liver associations committees, including the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD), and was a member of the EASL Scientific Committee and Governing Board from 2007–2010 and the AASLD International Relations Advisory Committee from 2010–2012.

 

CME Credits

 uems

 

The Live webinar on COVID-19 vaccination in patients with liver disease, date 09 March 2021, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s).

Each medical specialist should claim only those credits that he/she actually spent in the live educational activity on 09 March 2021.

Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.